Zimmer Biomet Holdings Inc (ZBH)
合理估值基本面
63
价格
$88.05
市值
$17.48B
第一部分 · 这家公司值多少
概览
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$8.51B
最近12个月（截至2026/6/30）
净利润
$807M
最近12个月（截至2026/6/30）
自由现金流
$1.47B
股东权益合计
$12.70B
负债合计
$10.39B
流动比率
1.69
利息覆盖率
4.17
债务/EBITDA
3.41
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$110.62
当前价格
$88.05
安全边际
+20.4%
公允价值区间
$71.91 - $149.34
所用估值方法之间的离散区间，并非经过统计校准的置信区间。
估算方法
估值指标
市盈率（P/E）
21.56
ROE
5.6%
市净率（P/B）
1.34
P/FCF
11.12
毛利率
69.9%
ROIC
4.8%
盈利能力雷达图
价值创造（经济护城河）
ROIC
4.8%
WACC
6.5%
ROIC − WACC
-1.7 pp
ROIC 低于资本成本：公司每投入一美元都在毁灭价值。
基本面分析标准
通过（16）
- EPS shows upward trend
- Gross Margin 69.9%
- P/FCF 11.12
- P/B Ratio 1.34
- Debt/Equity ratio
- Operating Margin 14.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Earnings Surprise avg 3.4%
- Earnings Quality (OCF/NI) 2.16
- Share Dilution -2.6%
- Piotroski F-Score 5/9
未通过（10）
- EPS CAGR 0.47%
- Price CAGR -0.69%
- ROIC 4.8%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- ROE 6.3%
- Revenue Growth 5Y 3.2%
- Analyst Consensus 33% Buy
- Net Margin Trend 9.5% vs 10.5%
不可用（2）
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-评分
信号混杂：部分领域需关注
盈利质量
高质量：盈利有现金流支撑
股权稀释
正在回购股份，对股东友好
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Ivan Tornos | President, CEO & Chairman of the Board | 50 |
| Mr. Wilfred van Zuilen | Group President of Europe, Middle East & Africa | 55 |
| Mr. JehanZeb Noor | Senior VP, Chief Strategy, Business Development, Innovation & Transformation Officer | 43 |
| Mr. Kevin R. Thornal | Group President of Global Businesses & Americas | 51 |
| Mr. Paul A. Stellato | Interim CFO, VP, Controller & Chief Accounting Officer | 50 |
| Mr. Shaun Braun | Senior VP & Chief Information and Technology Officer | - |
| Dr. Jonathan M. Vigdorchik M.D. | Chief Science, Technology & Medical Affairs Officer | - |
| Mr. David M. DeMartino | Senior Vice President of Investor Relations | - |
| Mr. Chad F. Phipps J.D. | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary | 53 |
| Ms. Angela Main | Senior VP, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific | - |
审计风险
6
董事会风险
8
薪酬风险
8
股东权利风险
4
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for ZBH, sourced from Markets Gazette.